"We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 and type 2 patients ... William ...

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...